Table 4.

JAK2V617F VAF dynamics in prospective PV clinical trials

TreatmentBaseline JAK2V617F VAF (%)12-month JAK2V617F VAF (%)24-month JAK2V617F VAF (%)60-month JAK2V617F VAF (%)
LOW-PV61,79  Phlebotomy 35 36   
PROUD-PV62  BAT, HU 42 18 25 44 
RESPONSE-263  BAT, HU 66 72   
RESPONSE-13  BAT, HU 76 77   
LOW-PV61,79  Ropeginterferon 35 25 12  
PROUD-PV62  Ropeginterferon 37 24 14 8 
Pegasys in PV80  Peginterferon alfa-2a 45 22 5  
COMBI71  Peginterferon alfa-2a or peginterferon alfa-2b and ruxolitinib 47  12  
COMBI-II81  Peginterferon alfa-2a and ruxolitinib 47  6  
TreatmentBaseline JAK2V617F VAF (%)12-month JAK2V617F VAF (%)24-month JAK2V617F VAF (%)60-month JAK2V617F VAF (%)
LOW-PV61,79  Phlebotomy 35 36   
PROUD-PV62  BAT, HU 42 18 25 44 
RESPONSE-263  BAT, HU 66 72   
RESPONSE-13  BAT, HU 76 77   
LOW-PV61,79  Ropeginterferon 35 25 12  
PROUD-PV62  Ropeginterferon 37 24 14 8 
Pegasys in PV80  Peginterferon alfa-2a 45 22 5  
COMBI71  Peginterferon alfa-2a or peginterferon alfa-2b and ruxolitinib 47  12  
COMBI-II81  Peginterferon alfa-2a and ruxolitinib 47  6  

BAT, best available therapy.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal